Stereotactic Ablative Radiosurgery for Lung Cancer
(GPS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method for treating early-stage lung cancer or single lung tumors from another cancer using a precise form of radiation called Stereotactic Ablative Radiosurgery (SABR). Small beacons placed near the tumor guide the radiation, ensuring it targets the cancer accurately while sparing nearby healthy tissue. This method is known as Calypso Guided High Precision Stereotactic Ablative Radiosurgery. Individuals with small non-small cell lung cancer tumors or a single lung metastasis who cannot or do not want surgery might be suitable candidates. Participants should be able to undergo a procedure called bronchoscopy and have reasonable lung function. As an unphased trial, this study offers patients the chance to explore cutting-edge treatment options that may improve their quality of life.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this technique is safe for lung cancer patients?
Research has shown that Calypso-guided radiotherapy, as used in this trial, is generally manageable for patients. Studies indicate that Calypso beacons in Stereotactic Ablative Radiosurgery (SABR) enhance the accuracy of targeting lung tumors. This technique focuses radiation on the tumor while safeguarding surrounding healthy tissue.
One study found that using these beacons in SABR treatments can enhance safety by reducing radiation exposure to healthy tissue. The beacons provide real-time information about the tumor's location, leading to more precise treatment.
Another study reported that SABR achieved a 98% success rate in controlling the primary tumor over three years for early-stage lung cancer, suggesting the treatment is both effective and safe in the long term.
Overall, evidence suggests this approach is a promising and safe option for treating lung cancer.12345Why are researchers excited about this trial?
Researchers are excited about Calypso Guided High Precision Stereotactic Ablative Radiosurgery for lung cancer because it offers real-time tracking of the tumor during treatment. Unlike traditional radiation therapy, which can sometimes affect healthy tissue due to movement, this method uses implanted transponder beacons to precisely target the cancerous area, minimizing damage to surrounding healthy tissue. This precision not only enhances the effectiveness of the treatment but also reduces side effects, making it a promising option for patients.
What evidence suggests that Calypso Guided High Precision Stereotactic Ablative Radiosurgery is effective for lung cancer?
Research has shown that Stereotactic Ablative Radiosurgery (SABR) effectively treats early-stage Non-Small Cell Lung Cancer. Studies have found that this treatment prevents cancer growth in the treated area for 90% to 96% of patients over three years. SABR has also been associated with better survival rates over five years compared to traditional treatments. In this trial, Calypso beacons, part of the Real-Time Position Transponder Beacons arm, track the tumor's position in real time, allowing for precise targeting. This precision reduces harm to nearby healthy tissues and may enhance the treatment's success.12367
Are You a Good Fit for This Trial?
This trial is for adults over 18 with early-stage Non-Small Cell Lung Cancer or a single lung metastasis who can't have surgery or choose not to. They must be able to undergo bronchoscopy, have decent lung function (DLCO ≥35%, FEV1 ≥0.8L), and an ECOG status of 0-2, indicating they are relatively active. Tumors should be in the middle/lower lobes of the lung but not too close to the chest wall or main airways.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase I Treatment
Quality assurance assessments and familiarization with the use of endobronchial implanted real-time tumor tracking transponder beacons. Standard SABR treatment with beacon data collection for post-treatment quality assurance.
Phase II Treatment
Specialized SABR radiotherapy using real-time tumor tracking with transponder beacons, employing respiratory gating and smaller planning target volume expansion margins.
Follow-up
Participants are monitored for safety, effectiveness, and quality of life post-treatment. Includes toxicity assessments and tumor control evaluations.
What Are the Treatments Tested in This Trial?
Interventions
- Calypso Guided High Precision Stereotactic Ablative Radiosurgery
- Real-Time Position Transponder Beacons
Find a Clinic Near You
Who Is Running the Clinical Trial?
CancerCare Manitoba
Lead Sponsor
Varian Medical Systems
Industry Sponsor
Dow R. Wilson
Varian Medical Systems
Chief Executive Officer since 2012
MBA from Dartmouth's Amos Tuck School of Business, BA from Brigham Young University
Dr. Deepak Khuntia
Varian Medical Systems
Chief Medical Officer since 2020
MD from the University of Cambridge, PhD from the University of Leicester